[go: up one dir, main page]

MX2009005398A - Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. - Google Patents

Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.

Info

Publication number
MX2009005398A
MX2009005398A MX2009005398A MX2009005398A MX2009005398A MX 2009005398 A MX2009005398 A MX 2009005398A MX 2009005398 A MX2009005398 A MX 2009005398A MX 2009005398 A MX2009005398 A MX 2009005398A MX 2009005398 A MX2009005398 A MX 2009005398A
Authority
MX
Mexico
Prior art keywords
chronic inflammatory
methods
inflammatory diseases
treating chronic
csf antagonist
Prior art date
Application number
MX2009005398A
Other languages
English (en)
Inventor
Christopher R Bebbington
Geoffrey T Yarranton
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of MX2009005398A publication Critical patent/MX2009005398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La invención está basada en el descubrimiento de que se pueden usar antagonistas de GM-CSF para el tratamiento de enfermedades inflamatorias crónicas tales como artritis reumatoide. Así, la invención proporciona métodos para administrar un antagonista de GM-CSF, por ejemplo un anticuerpo de GM-CSF y compuestos anit-foliato, por ejemplo, metotrexato, a un paciente que tiene RA y composiciones farmacéuticas que comprenden tales antagonistas.
MX2009005398A 2006-11-21 2007-11-21 Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. MX2009005398A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86078006P 2006-11-21 2006-11-21
US90274207P 2007-02-21 2007-02-21
PCT/US2007/085402 WO2008064321A2 (en) 2006-11-21 2007-11-21 Methods of treating chronic inflammatory diseases using a gm-csf antagonist

Publications (1)

Publication Number Publication Date
MX2009005398A true MX2009005398A (es) 2009-08-20

Family

ID=39386167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005398A MX2009005398A (es) 2006-11-21 2007-11-21 Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.

Country Status (15)

Country Link
US (2) US20080206241A1 (es)
EP (2) EP2402013A1 (es)
JP (1) JP5410293B2 (es)
KR (1) KR101517251B1 (es)
CN (2) CN101605547A (es)
AU (1) AU2007323541B2 (es)
BR (1) BRPI0719109A2 (es)
CA (1) CA2670288C (es)
EA (1) EA200900709A1 (es)
ES (1) ES2432173T3 (es)
IL (1) IL198829A0 (es)
MX (1) MX2009005398A (es)
NZ (1) NZ598345A (es)
SG (1) SG176503A1 (es)
WO (1) WO2008064321A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005398A (es) 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PT2215119E (pt) 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
JP2011510015A (ja) * 2008-01-15 2011-03-31 カロバイオス ファーマシューティカルズ インコーポレイティッド Ｇｍ−ｃｓｆアンタゴニストを用いて骨減少障害を治療する方法
EP2282757B1 (en) * 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101852915B1 (ko) 2008-04-28 2018-04-27 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
CA2746827C (en) * 2008-12-22 2018-01-23 The University Of Melbourne Osteoarthritis treatment
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
WO2010093814A1 (en) * 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
BRPI1006514A2 (pt) * 2009-05-05 2019-01-08 Morphosys Ag antagonista do gm-csf
CA2839513A1 (en) * 2011-07-06 2013-01-10 Morphosys Ag Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP3039039B1 (en) * 2013-08-30 2021-03-10 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP6360696B2 (ja) * 2014-03-18 2018-07-18 日本光電工業株式会社 血液検査装置および血液検査方法
CN106456761A (zh) * 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
WO2018031967A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
IL265331B2 (en) * 2016-09-19 2024-01-01 I Mab Anti-gm-csf antibodies and uses thereof
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US20220040229A1 (en) * 2018-10-31 2022-02-10 Humanigen, Inc. Materials and methods for treating cancer
CN115605508A (zh) * 2020-03-08 2023-01-13 赫曼尼根公司（Us） 用于治疗冠状病毒感染和所产生的炎症诱导的肺损伤的方法
KR20230124910A (ko) * 2020-12-04 2023-08-28 씨에스엘 이노베이션 피티와이 엘티디 염증성 피부 상태 치료 방법
US20240317846A1 (en) * 2021-03-08 2024-09-26 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
HUT63181A (en) * 1989-07-14 1993-07-28 Schering Corp Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
AU2003217386B2 (en) * 2002-02-13 2008-06-26 Ludwig Institute For Cancer Research Humanized GM-CSF antibodies
GB0224082D0 (en) * 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
EP1615659B1 (en) * 2003-03-12 2014-04-16 Genentech, Inc. Use of bv8 and/or eg-vegf to promote hematopoiesis
TWI376370B (en) * 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
WO2005069970A2 (en) 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
MX2007000564A (es) * 2004-07-16 2007-03-30 Kyorin Seiyaku Kk Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
PT2343380T (pt) * 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
CA2608498C (en) 2005-05-18 2017-04-04 Morphosys Ag Anti-gm-csf antibodies and uses therefor
US20080305079A1 (en) * 2006-01-06 2008-12-11 Mount Sinai School Of Medicine Of New York University Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
DK1999152T3 (da) 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
DE102006033837A1 (de) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
MX2009005398A (es) 2006-11-21 2009-08-20 Kalobios Pharmaceuticals Inc Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.

Also Published As

Publication number Publication date
US20080206241A1 (en) 2008-08-28
KR101517251B1 (ko) 2015-05-07
CN105435223A (zh) 2016-03-30
CA2670288A1 (en) 2008-05-29
AU2007323541B2 (en) 2012-01-19
SG176503A1 (en) 2011-12-29
CN101605547A (zh) 2009-12-16
KR20090110827A (ko) 2009-10-22
JP5410293B2 (ja) 2014-02-05
NZ598345A (en) 2013-09-27
IL198829A0 (en) 2010-02-17
CA2670288C (en) 2015-10-27
JP2010510323A (ja) 2010-04-02
EP2402013A1 (en) 2012-01-04
ES2432173T3 (es) 2013-12-02
WO2008064321A2 (en) 2008-05-29
EA200900709A1 (ru) 2009-12-30
EP2101780B1 (en) 2013-10-09
WO2008064321A3 (en) 2008-10-02
AU2007323541A1 (en) 2008-05-29
US20150246121A1 (en) 2015-09-03
BRPI0719109A2 (pt) 2013-12-10
EP2101780A2 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
UA95940C2 (uk) Азаіндоли як інгібітори кіназ януса
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
EA200970342A1 (ru) Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
JO3327B1 (ar) تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
EA201001162A1 (ru) Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf
ATE542814T1 (de) Pyrazinkinaseinhibitoren
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
WO2008063898A3 (en) Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration